Teriparatide
What it is
Teriparatide is a recombinant form of the first 34 amino acids at the N-terminus of human parathyroid hormone, commonly written as PTH(1-34). It is the active fragment of parathyroid hormone that engages the PTH1 receptor, and it is grouped with the osteoanabolic, or bone-forming, agents. This is a neutral reference entry describing its identity, regulatory status, and handling, not a usage guide.
Research context and categorization
Teriparatide sits in the peptide hormone family and, more specifically, the osteoanabolic or bone-metabolism category. Unlike agents that slow bone breakdown, it is characterized as a bone-formation compound, and much of the literature focuses on how the pattern of exposure changes its effect. It is commonly discussed in relation to the observation that continuous exposure to parathyroid hormone tends to favor bone resorption, while intermittent, once-daily exposure is described as favoring new bone formation over breakdown.
Because it is an approved medicine, its established use is defined by its labeling rather than by open-ended investigation. It is studied in the context of osteoporosis and bone mineral density, and comparative work has looked at it alongside related molecules such as abaloparatide and romosozumab and against biosimilar versions. Any bone-metabolism, healing, or tissue-repair topics discussed beyond its approved indication remain investigational and should not be read as confirmed or approved outcomes.
Status
- Regulatory status: FDA-approved for a specific indication. Teriparatide (brand Forteo, Eli Lilly) was approved in November 2002 for osteoporosis in defined high-fracture-risk populations, and additional recombinant and biosimilar versions (for example Bonsity, approved 2019) have since reached the market. Material sold by research-supply vendors is labeled research-only and is a separate category from the approved drug product.
- Sport status: Prohibited under the WADA Prohibited List. As a peptide hormone it is discussed under the peptide hormones, growth factors, related substances, and mimetics class (S2). A Therapeutic Use Exemption may be considered where a documented medical need exists. Confirm current status directly against the WADA Prohibited List, which is revised annually.
Reconstitution notes (general)
For a lyophilized (freeze-dried) powder, concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, adding 2 mL to a 10 mg vial gives 5 mg/mL. Adding less water yields a more concentrated solution and adding more yields a more dilute one, with the peptide mass unchanged. Use the calculator at our reconstitution and blend calculators to work out a target concentration before drawing anything up.
Dilution and handling notes (compound-specific)
Two very different formats exist, so the handling depends on which one is in front of you.
The approved injectable is a ready-to-use liquid, not a powder. It is supplied as a sterile, colorless, clear, isotonic solution at roughly 250 mcg/mL, already filled into a glass cartridge inside a single-patient multi-dose pen. It is buffered to about pH 4.0 with an acetate system, with mannitol as a bulking and stabilizing agent and metacresol as a preservative. Nothing is mixed, and no reconstitution step applies to this form.
Research-grade material more often ships as a lyophilized powder in the vial and is reconstituted before use. PTH(1-34) is a short, generally well-behaved peptide that goes into aqueous solution readily and clears without gelling. Because its stable environment is mildly acidic, it tends to be most soluble and stable around pH 3 to 5, so a slightly acidic diluent supports it while neutral or alkaline conditions are less favorable. Typical reconstitution volumes with bacteriostatic water fall in roughly the 1 to 3 mL per vial range depending on vial size and the concentration wanted, and some multi-vial research kits arrive already premixed to about 1 mL. A compound-specific quirk is worth noting: reports on lyophilized PTH(1-34) indicate that once it is brought back into solution, physical stability varies with concentration and storage temperature, and precipitation can appear within roughly two to four weeks in some samples, whereas equivalent material that was never lyophilized has stayed clear in the liquid state for as long as about twelve weeks. Like most peptides it is also sensitive to heat, agitation, and prolonged light and is prone to oxidation and deamidation over time, so haze, particles, or aggregation signal degradation rather than a mixing error. Add the diluent gently down the vial wall and swirl rather than shaking to limit foaming, and keep the reconstituted solution cold and shielded from light.
Handling and storage
Refrigerate at 2 to 8 degrees Celsius and keep out of light. Wipe the stopper with alcohol before each puncture, and label the vial with the mix date. Observe the general ~4-week refrigerated in-use window as a practical ceiling, which lines up with the labeled 28-day discard period for the in-use pen. Inspect before every use and discard anything that turns cloudy or discolored or that shows visible floaters.
Related reading
Tools and supplies
- Reconstitution & blend calculators
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.